Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03126630
Recruitment Status : Recruiting
First Posted : April 24, 2017
Last Update Posted : September 10, 2019
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Tracking Information
First Submitted Date  ICMJE April 20, 2017
First Posted Date  ICMJE April 24, 2017
Last Update Posted Date September 10, 2019
Actual Study Start Date  ICMJE February 8, 2018
Estimated Primary Completion Date February 2, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 2, 2018)
  • Recommended phase 2 dose of anetumab ravtansine with combination of pembrolizumab [ Time Frame: Up to 21 days ]
    An early safety analysis will be performed after the first 6 patients have been accrued to the safety lead-in portion of the study at dose level 1 and observed for one cycle. If 2 or more of the first 6 patients experience a dose limiting toxicities, then the starting dose level will be adjusted and additional cohorts may be evaluated. All patients that have received any amount of the combination anetumab ravtansine and pembrolizumab will be evaluable for toxicity.
  • Confirmed tumor response rate assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria (Phase II) [ Time Frame: Up to 2 years ]
    The proportion of successes will be estimated in each group by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated in each arm. Comparison of confirmed response rates between the two treatment groups will be performed using a one-sided z-test with pooled variance at significance level 0.10.
Original Primary Outcome Measures  ICMJE
 (submitted: April 20, 2017)
  • Dose limiting toxicity assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.03 [ Time Frame: Up to 21 days ]
    An early safety analysis will be performed after the first 6 patients have been accrued to the safety lead-in portion of the study at dose level 1 and observed for one cycle. If 2 or more of the first 6 patients experience a dose limiting toxicities, then the starting dose level will be adjusted and additional cohorts may be evaluated.
  • Overall response rate (Phase II) [ Time Frame: Up to 2 years ]
    The proportion of successes will be estimated in each arm by the number of successes divided by the total number of evaluable patients. Exact binomial ninety-five percent confidence intervals for the true success proportion will be calculated in each arm. Comparison of overall response rates between the two treatment groups will be performed using a one-sided chi-square test at significance level 0.10.
Change History Complete list of historical versions of study NCT03126630 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: March 2, 2018)
  • Duration of response defined as evaluable patients who achieved noted to be a partial response or complete response based Response Evaluation Criteria in Solid Tumors version 1.1 criteria [ Time Frame: Up to 2 years ]
    Will be estimated using the method of Kaplan-Meier. The comparison of duration of response between two treatment arms will be based on the log-rank test. This calculation will start with the date of start of treatment.
  • Overall survival [ Time Frame: From the start of treatment to death due to any cause, assessed up to 2 years ]
    Will be estimated using the method of Kaplan-Meier. The comparison of overall survival between two treatment arms will be based on the log-rank test.
  • Progression free survival [ Time Frame: From the start of treatment to the earliest date of documentation of disease progression or death due to any cause, assessed up to 2 years ]
    Will be estimated using the method of Kaplan-Meier. The comparison of progression-free survival between two treatment arms will be based on the log-rank test.
  • Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 30 days after last dose of study drug ]
    The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed for each arm to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. The overall adverse event rates for grade 3 or higher hematologic and non-hematologic adverse events at least possibly related to treatment will be compared between the two treatment groups using the Chi-square test (or Fisher's exact test if the data in the contingency table is sparse).
  • Pharmacokinetics of anetumab ravtansine [ Time Frame: Days 1 and 3 of courses 1 and 8 ]
    Will be largely descriptive. Changes over time will be plotted and assessed for each patient.
  • Change in megakaryocyte potentiating factor levels assessed in tumor [ Time Frame: Baseline up to 2 years ]
    Relative changes in biomarker levels will be compared by best overall response groups using the non-parametric Wilcoxon rank-sum test. Also, the associations between changes in megakaryocyte potentiating factor levels and ordered response categories (i.e. complete response-partial response-stable disease-progressive disease) will be assessed with the Jonckheere-Terpstra test for trend.
  • Mononuclear phagocyte system -FcgammaRs and chemokine mediators of mononuclear phagocyte system [ Time Frame: Up to 2 years ]
    The mean equivalent soluble fluorophore and antibody bound to cell (ABC) will be determined for each specimen. Linear regression will be used to explore the linear relationship between the continuous values of these mononuclear phagocyte system-FcgammaRs probes and anetumab ravtansine levels. The concentrations of CCL2 and CCL5 will be determined for each specimen. Linear regression will be used to explore the linear relationship between the continuous values of these chemokines and anetumab ravtansine levels.
Original Secondary Outcome Measures  ICMJE
 (submitted: April 20, 2017)
  • Change in megakaryocyte potentiating factor levels assessed in tumor [ Time Frame: Baseline up to 2 years ]
    Relative changes in biomarker levels will be compared by best overall response groups using the non-parametric Wilcoxon rank-sum test. Also, the associations between changes in megakaryocyte potentiating factor levels and ordered response categories (i.e. complete response-partial response-stable disease-progressive disease) will be assessed with the Jonckheere-Terpstra test for trend.
  • Duration of response defined as evaluable patients who achieved noted to be a partial response or complete response based Response Evaluation Criteria in Solid Tumors version 1.1 criteria [ Time Frame: Up to 2 years ]
    Will be estimated using the method of Kaplan-Meier. The comparison of duration of response between two treatment arms will be based on the log-rank test.
  • Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 30 days after last dose of study drug ]
    The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed for each arm to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. The overall adverse event rates for grade 3 or higher hematologic and non-hematologic adverse events at least possibly related to treatment will be compared between the two treatment groups using the Chi-square test (or Fisher's exact test if the data in the contingency table is sparse).
  • Mononuclear phagocyte system -FcgammaRs and chemokine mediators of mononuclear phagocyte system [ Time Frame: Up to 2 years ]
    The mean equivalent soluble fluorophore and antibody bound to cell (ABC) will be determined for each specimen. Linear regression will be used to explore the linear relationship between the continuous values of these mononuclear phagocyte system-FcgammaRs probes and anetumab ravtansine levels. The concentrations of CCL2 and CCL5 will be determined for each specimen. Linear regression will be used to explore the linear relationship between the continuous values of these chemokines and anetumab ravtansine levels.
  • Overall survival [ Time Frame: From registration to death due to any cause, assessed up to 2 years ]
    Will be estimated using the method of Kaplan-Meier. The comparison of overall survival between two treatment arms will be based on the log-rank test.
  • Overall survival of patients who cross-over [ Time Frame: Time of re-registration to death due to any cause, assessed up to 2 years ]
    The distribution of survival time will be estimated using the method of Kaplan-Meier.
  • Pharmacokinetics of anetumab ravtansine and pembrolizumab [ Time Frame: Days 1 and 3 of courses 1 and 8 ]
    Assessed by blood samples.
  • Progression free survival [ Time Frame: From registration to the earliest date of documentation of disease progression or death due to any cause, assessed up to 2 years ]
    Will be estimated using the method of Kaplan-Meier. The comparison of progression-free survival between two treatment arms will be based on the log-rank test.
  • Progression free survival of patient who cross-over [ Time Frame: Time of re-registration to the earliest date of documentation of disease progression after the cross-over or death due to any cause, assessed up to 2 years ]
    Will be estimated using the method of Kaplan-Meier.
Current Other Pre-specified Outcome Measures
 (submitted: March 2, 2018)
  • Measurements of Bim in TTR [ Time Frame: Up to 2 years ]
    Measurements of Bim in TTR as a predictor of responses to treatment. Is anticipated that a non-parametric test such as the Mann-Whitney test should be used to compare Bim in TTR between subjects that do and do not respond to therapy.
  • Measurements of soluble PD-L1 [ Time Frame: Up to 2 years ]
    Measurements of soluble PD-L1 as a predictor of responses to treatment. Is anticipated that a non-parametric test such as the Mann-Whitney test should be used to compare soluble PD-L1 between subjects that do and do not respond to therapy.
  • PD-L1 expression in archival tissue [ Time Frame: Up to 2 years ]
    PD-L1 expression in archival tissue as a predictive marker of response to pembrolizumab-based therapy. Will compare whether there is a difference in the number of responders with 50% or greater PD-L1 tumor cell expression and those without with the Chi-square test (or Fisher's exact test if the data in the contingency table is sparse).
  • Patient reported outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) [ Time Frame: Up to 2 years ]
Original Other Pre-specified Outcome Measures
 (submitted: April 20, 2017)
  • Measurements of Bim in TTR [ Time Frame: Up to 2 years ]
    Measurements of Bim in TTR as a predictor of responses to treatment. Is anticipated that a non-parametric test such as the Mann-Whitney test should be used to compare Bim in TTR between subjects that do and do not respond to therapy.
  • Measurements of soluble PD-L1 [ Time Frame: Up to 2 years ]
    Measurements of soluble PD-L1 as a predictor of responses to treatment. Is anticipated that a non-parametric test such as the Mann-Whitney test should be used to compare soluble PD-L1 between subjects that do and do not respond to therapy.
  • PD-L1 expression in archival tissue [ Time Frame: Up to 2 years ]
    PD-L1 expression in archival tissue as a predictive marker of response to pembrolizumab-based therapy. Will compare whether there is a difference in the number of responders with 50% or greater PD-L1 tumor cell expression and those without with the Chi-square test (or Fisher's exact test if the data in the contingency table is sparse).
 
Descriptive Information
Brief Title  ICMJE Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Official Title  ICMJE Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
Brief Summary This randomized phase I/II trial studies the side effects and how well pembrolizumab with or without anetumab ravtansine work in treating patients with mesothelin-positive pleural mesothelioma. Monoclonal antibodies, such as anetumab ravtansine and pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Detailed Description

PRIMARY OBJECTIVES:

I. Determine the dose of anetumab ravtansine that is safe in combination with MK-3475 (pembrolizumab) to be used in the randomized phase 2 study. (Phase I safety lead-in) II. Determine if the overall response rate of the combination of anetumab ravtansine and MK-3475 (pembrolizumab) is superior to MK-3475 (pembrolizumab) alone. (Phase II)

SECONDARY OBJECTIVE:

I. To determine the progression free survival of anetumab ravtansine and MK-3475 (pembrolizumab) compared to MK-3475 (pembrolizumab) alone.

II. To evaluate the pharmacodynamic effects of anetumab ravtansine and MK-3475 (pembrolizumab) on soluble megakaryocyte potentiating factor (MPF).

III. To evaluate the pharmacokinetics of anetumab ravtansine and MK-3475 (pembrolizumab).

IV. To evaluate mononuclear phagocyte system (MPS) function, FcgammaRs, hormone and chemokine mediators as methods to evaluate factors affecting the pharmacokinetics and pharmacodynamics of these agents.

V. To determine the incidence of antibodies directed against anetumab ravtansine.

TERTIARY OBJECTIVE:

I. To determine whether elevations in Bim in TTR predict responses to treatment and whether its detection is dynamic with treatment.

II. To determine whether soluble PD-L1 predicts responses to treatment and whether its detection is dynamic with treatment.

III. To evaluate PD-L1 expression in archival tissue as a predictive marker of response to MK-3475 (pembrolizumab)-based therapy.

IV. To explore the symptomatic adverse events (AE) for tolerability of each treatment group using patient reported outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE).

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.

GROUP II: Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 12 months.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Mesothelin Positive
  • Pleural Malignant Mesothelioma
Intervention  ICMJE
  • Biological: Anetumab Ravtansine
    Given IV
    Other Name: BAY 94-9343
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Biological: Pembrolizumab
    Given IV
    Other Names:
    • Keytruda
    • Lambrolizumab
    • MK-3475
    • SCH 900475
  • Other: Pharmacological Study
    Correlative studies
Study Arms  ICMJE
  • Active Comparator: Group I (pembrolizumab)
    Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.
    Interventions:
    • Other: Laboratory Biomarker Analysis
    • Biological: Pembrolizumab
    • Other: Pharmacological Study
  • Experimental: Group II (anetumab ravtansine, pembrolizumab)
    Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
    Interventions:
    • Biological: Anetumab Ravtansine
    • Other: Laboratory Biomarker Analysis
    • Biological: Pembrolizumab
    • Other: Pharmacological Study
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 20, 2017)
134
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE February 2, 2020
Estimated Primary Completion Date February 2, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • PRE-REGISTRATION
  • Patients must have histologically or cytologically confirmed malignant pleural mesothelioma; for phase 2 of this study only, the malignant tissue must show moderate or stronger mesothelin expression in 30% of tumor cells by a companion assay for the patient to be eligible for and registered to the study; for patients in pre-registration for phase 2, submit slides or a tissue block from an archived tissue sample or a fresh tissue sample from biopsy if archived tissue is not available to the central lab for the mesothelin expression assay; central review of pathology will not be performed
  • Patients must have received platinum based chemotherapy; the submission of a tissue sample for the mesothelin assay to determine eligibility for the study may occur prior to, during or after receipt of the frontline chemotherapy; patients will not be required to submit another tissue sample after receipt of the chemotherapy
  • REGISTRATION
  • Patients who participate in the phase 1 portion of the trial are not required to have measurable disease; patients who participate in the randomized phase 2 portion of the clinical trial must have measurable disease; for pleural disease, this is defined as at least one lesion that can be accurately measured perpendicular to the chest wall or mediastinum that is >= 10 mm (>= 1 cm); for extra pleural disease, measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 10 mm (>= 1 cm) for non-nodal lesions and >= 15 mm (>= 1.5 cm) for nodal lesions with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
  • Patients must have received platinum-based therapy with or without bevacizumab, but may not have received a PD-1, PD-L1 or PD-L2 inhibitor
  • Eastern Cooperative Oncology Group (ECOG) performance status < 2 (Karnofsky >= 60%)
  • Leukocytes >= 3,000/mcL
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Total bilirubin within normal institutional limits
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (ULN)
  • Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
  • International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN
  • Partial thromboplastin time (PTT) or activated PTT (aPTT) =< 1.5 x ULN
  • Patients on a stable dose of anti-coagulation therapy will be allowed to participate if they have no signs of bleeding or clotting and the INR/PT and PTT/aPTT results are compatible with an acceptable risk-benefit ratio as per the investigator's discretion
  • Negative serum pregnancy test for females of child bearing potential; females are considered to not be of child bearing potential if they are either:

    • Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age, a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient);
    • Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening;
    • Has a congenital or acquired condition that prevents childbearing
  • Requirement to use contraception prior to, during and after the completion of the study; women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of the study and 4 months after completion of anetumab ravtansine or pembrolizumab administration; acceptable methods of contraception are:

    • Single method (1 of the following is acceptable):

      • Intrauterine device (IUD)
      • Vasectomy of a female patient's male partner
      • Contraceptive rod implanted into the skin
    • Combination method (requires use of 2 of the following):

      • Diaphragm with spermicide (cannot be used in conjunction with cervical cap/spermicide)
      • Cervical cap with spermicide (nulliparous women only)
      • Contraceptive sponge (nulliparous women only)
      • Male condom or female condom (cannot be used together)
      • Hormonal contraceptive: oral contraceptive pill (estrogen/progestin pill or progestin-only pill), contraceptive skin patch, vaginal contraceptive ring, or subcutaneous contraceptive injection
    • Abstinence (relative to heterosexual activity) can be used as the sole method of contraception if it is consistently employed as the patient's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and Institutional Review Boards (IRBs); periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception
    • If there is any question that a patient will not reliably comply with the requirements for contraception, that patient should not be entered into the study; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Ability to understand and the willingness to sign a written informed consent document; patients with impaired decision making capacity may be eligible if they have a Legal Authorized representative or caretaker available

Exclusion Criteria:

  • Patients who have received any monoclonal antibody therapy within 4 weeks prior to entering the study
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1); Note: Patients with =< grade 2 neuropathy or =< grade 2 alopecia are an exception to this criterion and may qualify for the study; Note: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
  • Patients who are receiving any other investigational agents
  • Patients with known brain metastases with progressive neurologic dysfunction, requirement of steroids and lack of improvement on head imaging obtained prior to consent to this clinical trial should be excluded; patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging using the identical imaging modality for each assessment, either magnetic resonance imaging [MRI] or computed tomography [CT] scan, for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment; patients with carcinomatosis meningitis should also be excluded
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to anetumab ravtansine or MK-3475 (pembrolizumab)
  • Patients receiving any medications or substances that are inhibitors or inducers of CYP3A4 are ineligible; these include herbal preparation containing CYP3A4 inducers (e.g., St. John's wort), grapefruit and grapefruit juice (CYP3A4 inhibitor) within 2 weeks before the start of study treatment; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
  • Patients are prohibited from receiving the following therapies during the screening and treatment phases of this trial:

    • Antineoplastic systemic chemotherapy or biological therapy
    • Immunotherapy not specified in this protocol
    • Chemotherapy not specified in this protocol
    • Investigational agents other than anetumab ravtansine and MK-3475 (pembrolizumab)
    • Radiation therapy

      • Note: Radiation therapy to a symptomatic solitary lesion or to the brain may be considered on an exceptional case by case basis after consultation with Cancer Therapy Evaluation Program (CTEP); the patient must have clear measurable disease outside the radiated field; administration of palliative radiation therapy will be considered clinical progression for the purposes of determining progression free survival (PFS)
    • Live vaccines within 30 days prior to the first dose of trial treatment and while participating in the trial; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Chalmette-Guerin (BCG), and typhoid (oral) vaccine; seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed
    • Systemic glucocorticoids for any purpose other than to modulate symptoms from an event of suspected immunologic etiology; the use of physiologic doses of corticosteroids may be approved after consultation with the study principal investigator (PI) and CTEP
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with anetumab ravtansine or MK-3475 (pembrolizumab)
  • Human immunodeficiency virus (HIV)-positive patients are eligible provided they meet all the other protocol eligibility criteria including the following:

    • Undetectable HIV viral load by standard clinical assay
    • Willing to adhere to antiretroviral therapy that has minimal overlapping toxicity or pharmacokinetic interactions with protocol therapy
    • CD4+ T cell counts of 200/mm^3 or greater
    • No acquired immunodeficiency syndrome (AIDS)-defining events other within the past 12 months
    • Near normal life expectancy if not for the presence of the cancer Also, HIV-positive patients must not be on HIV medications considered to be inhibitors or inducers of CYP3A4
  • Patients who are known to have a history of or a finding of corneal epitheliopathy at pre-study are excluded
  • Known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer
  • Receipt of transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte colony-stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin) within 4 weeks prior to study treatment
  • Patient with active interstitial lung disease (ILD)/pneumonitis or a prior history of ILD/pneumonitis requiring treatment with steroids
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03126630
Other Study ID Numbers  ICMJE NCI-2017-00633
NCI-2017-00633 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
MC1721
10107 ( Other Identifier: Mayo Clinic Cancer Center LAO )
10107 ( Other Identifier: CTEP )
UM1CA186686 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party National Cancer Institute (NCI)
Study Sponsor  ICMJE National Cancer Institute (NCI)
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Aaron S Mansfield Mayo Clinic Cancer Center LAO
PRS Account National Cancer Institute (NCI)
Verification Date April 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP